|
In a recent Viewpoint published in JAMA, TRANSPERS collaborators Patricia A. Deverka, Grace A. Lin, and Kathryn A. Phillips address payer coverage considerations for an emerging technology: new blood tests for Alzheimer’s disease that could help diagnose the condition earlier and more easily. The authors define key evidence needs for potential payer coverage: clear and evidence-based guidelines, consideration of the equity implications, and assessment of the appropriate balance of access and coverage early in the disease trajectory versus the potential for overuse.
This publication already has almost 10,000 social media views, reflecting this issue's timeliness and importance. If blood tests are ultimately shown to have clinical utility, payer coverage will be crucial in ensuring equitable access and improving disparities in Alzheimer’s diagnosis and care, especially for underserved populations.
|